The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation

Robert Philibert; Joanna Moody; Willem Philibert; Meeshanthini V. Dogan; Eric A. Hoffman

doi:10.3390/genes14061233

Back

The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation

Journal article

Open access

Peer reviewed

The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation

Robert Philibert, Joanna Moody, Willem Philibert, Meeshanthini V. Dogan and Eric A. Hoffman

Genes, Vol.14(6), 1233

06/08/2023

DOI: 10.3390/genes14061233

PMCID: PMC10297911

PMID: 37372412

Files and links (1)

url

https://doi.org/10.3390/genes14061233View

Published (Version of record) Open Access

Abstract

Coronary heart disease (CHD) is the leading cause of death worldwide. However, current diagnostic tools for CHD, such as coronary computed tomography angiography (CCTA), are poorly suited for monitoring treatment response. Recently, we have introduced an artificial-intelligence-guided integrated genetic–epigenetic test for CHD whose core consists of six assays that determine methylation in pathways known to moderate the pathogenesis of CHD. However, whether methylation at these six loci is sufficiently dynamic to guide CHD treatment response is unknown. To test that hypothesis, we examined the relationship of changes in these six loci to changes in cg05575921, a generally accepted marker of smoking intensity, using DNA from a cohort of 39 subjects undergoing a 90-day smoking cessation intervention and methylation-sensitive digital PCR (MSdPCR). We found that changes in epigenetic smoking intensity were significantly associated with reversion of the CHD-associated methylation signature at five of the six MSdPCR predictor sites: cg03725309, cg12586707, cg04988978, cg17901584, and cg21161138. We conclude that methylation-based approaches could be a scalable method for assessing the clinical effectiveness of CHD interventions, and that further studies to understand the responsiveness of these epigenetic measures to other forms of CHD treatment are in order.

Epigenetics

coronary heart disease

DNA methylation

smoking cessation

treatment monitoring

Details

Title: Subtitle: The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation
Creators: Robert Philibert - University of Iowa
Joanna Moody - University of Iowa
Willem Philibert - University of Iowa
Meeshanthini V. Dogan - University of Iowa
Eric A. Hoffman - University of Iowa
Resource Type: Journal article
Publication Details: Genes, Vol.14(6), 1233
DOI: 10.3390/genes14061233
PMID: 37372412
PMCID: PMC10297911
NLM abbreviation: Genes (Basel)
eISSN: 2073-4425
Publisher: MDPI
Grant note: Cardio Diagnostics Inc. R44CA213507 / Robert Philibert, PI 5R01HL130883; S10OD026960 / Eric Hoffman, PI
Language: English
Date published: 06/08/2023
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Radiology; Psychiatry; Iowa Neuroscience Institute; Internal Medicine
Record Identifier: 9984438857302771

Metrics

10 Record Views

7 Times Cited - Web of Science

See more details